Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017 - 27 Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017" report to their offering.

Anaemia in Chronic Kidney Disease (Renal Anaemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Anaemia in Chronic Kidney Disease (Renal Anaemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 8, 1, 1, 6, 1 and 1 respectively.

Anaemia in Chronic Kidney Disease (Renal Anaemia) (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Anaemia in Chronic Kidney Disease (Renal Anaemia) - Overview
  3. Anaemia in Chronic Kidney Disease (Renal Anaemia) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Anaemia in Chronic Kidney Disease (Renal Anaemia) - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Anaemia in Chronic Kidney Disease (Renal Anaemia) - Companies Involved in Therapeutics Development
  • 3SBio Inc
  • Aevi Genomic Medicine Inc
  • Akebia Therapeutics Inc
  • Amgen Inc
  • Bayer AG
  • Betta Pharmaceuticals Co Ltd
  • Biocad
  • CCM Duopharma Biotech Bhd
  • Chong Kun Dang Pharmaceutical Corp
  • CJ HealthCare Corp
  • Dong-A Socio Holdings Co Ltd
  • FibroGen Inc
  • GlaxoSmithKline Plc
  • Intas Pharmaceuticals Ltd
  • Japan Tobacco Inc
  • JCR Pharmaceuticals Co Ltd
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Myungmoon pharmaceutical Co Ltd
  • Novartis AG
  • Panacea Biotec Ltd
  • Pfizer Inc
  • PharmaEssentia Corp
  • PhytoHealth Corp
  • Pieris Pharmaceuticals Inc
  • Reliance Life Sciences Pvt Ltd
  • Xenetic Biosciences Inc
  • Zydus Cadila Healthcare Ltd

For more information about this report visit https://www.researchandmarkets.com/research/gplgz8/anaemia_in

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Liver and Kidney Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Liver and Kidney Disorders Drugs